FDA Clearance Tracker · P030017-S344
Precision Spectra Spinal Cord Stimulator (SCS) System, Precision Novi Spinal Cord Stimulator (SCS) System, Precision Mon
Last checked: Nov 20, 2026Latest source record: Jul 12, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Jul 12, 2021
Approved
Time to decision
84 days
Received Apr 19, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P030017-S344
- Device name
- Precision Spectra Spinal Cord Stimulator (SCS) System, Precision Novi Spinal Cord Stimulator (SCS) System, Precision Mon
- Applicant
- Boston Scientific Corp
- Applicant location
- Valencia, CA
- Received
- Apr 19, 2021
- Decided
- Jul 12, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P030017
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for an update to the existing Software Bionic Navigator 3D version 4.0 to version 4.1. The updated software will be installed on the Clinician Programmer using the Bionic Navigator (BN) 3D 4.1 Installer (Model # SC-7101-410). This would allow one single software version (BN3D 4.1) to support all the Precision Spectra, Precision Novi, Precision Montage MRI, and Spectra WaveWriter and WaveWriter Alpha BCS Stimulators. The user interface of BN 3D 4.1 remain the same except for translations into various languages to support the international markets. In addition, BN 3D 4.1 introduces a new Sequence feature for additional flexibility when programming WaveWriter Alpha stimulators, in which a Sequence composed of various blocks of pulses can be created using a Composer tool and applied to the stimulators in a Programming Mode called Sequence Mode.The BN 3D software will be updated to Version 4.1 so that one single software version (BN3D 4.1) can support all the Precision Spectra, Precision Novi, Precision Montage MRI, and Spectra WaveWriter and WaveWriter Alpha BCS Stimulators. The user interface of BN 3D 4.1 will remain the same except for translations into various languages to support the international markets. In addition, BN 3D 4.1 introduces a new Sequence feature for additional flexibility when programming WaveWriter Alpha stimulators, in which a Sequence composed of various blocks of pulses can be created using a Composer tool and applied to the stimulators in a Programming Mode called Sequence Mode. Note that the new Sequence feature is only applicable to WaveWriter Alpha stimulators. The existing programming features for all stimulators remain the same.
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.